Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECOX: Sorafenib with Capecitabine and Oxaliplatin in Advanced HCC
NCT00752063Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Sep 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by The University of Hong Kong. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00752063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752063.